TurnCare

TurnCare

Pressure-injury prevention for high-acuity patients

Overview

TurnCare delivers B2B healthcare technology for high-acuity patients. Its core product, the Guardian System, is a therapeutic patient support surface that uses the VasoTactic algorithm to apply dynamic pressure gradients to the sacral region, helping maintain blood flow and reduce pressure injuries, and it includes an inflatable surface, a controller, and a real-time data dashboard. The company differentiates itself with its proprietary VasoTactic tech, data-driven decision support, and a usage-based payment model managed with Monetize360. Its goal is to reduce hospital-acquired pressure injuries, shorten hospital stays, and improve patient safety and throughput in acute care settings.

About TurnCare

Simplify's Rating
Why TurnCare is rated
C+
Rated C on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & Analytics

Enterprise Software

Healthcare

Company Size

N/A

Company Stage

N/A

Total Funding

N/A

Headquarters

Pequannock Township, New Jersey

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • May 2026 ISPOR abstracts reinforced HAPI burden and Guardian’s economic value.
  • Northwestern Memorial Hospital presented TurnCare’s real-world evidence at ISPOR 2026.
  • The December 2025 leadership buildout targets faster commercial scaling across U.S. hospitals.

What critics are saying

  • TurnCare admits Guardian lacks a large-scale trial and still requires Q2 repositioning.
  • Rental economics and reusable surfaces face commoditization from bed and wound-care vendors.
  • If hospitals reject non-replacement claims, Guardian loses differentiation and pricing power quickly.

What makes TurnCare unique

  • Guardian pairs VasoTactic with real-time iS analytics for sacral pressure management.
  • TurnCare is US-only and uses a rental model, easing hospital adoption.
  • JoLynn Short’s 2025 commercial leadership and Milligan’s 2024 board strengthen execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Company News

PR Newswire
Jan 14th, 2024
Turncare, Inc. Announces John F. Milligan, Phd, Former Ceo Of Gilead Sciences, Joins Board Of Directors

PALO ALTO, Calif., Jan. 11, 2024 /PRNewswire/ -- TurnCare, a leading medical technology and services company dedicated to advancing how hospitals manage high acuity patients, is proud to announce the addition of John F. Milligan, Ph.D., investor, innovator, and former CEO of Gilead, to its Board of Directors.Dr. Milligan, a seasoned industry veteran, played a pivotal role in growing Gilead from an early-stage private company into a multi-billion-dollar business with a global footprint. Dr. Milligan's contributions and expertise include the development of breakthrough new therapies to address healthcare epidemics like HIV and HCV, driving major acquisitions to create unique industry solutions, and scaling Gilead to over $21 Billion in worldwide sales with a market cap of $85 Billion

Recently Posted Jobs

Sign up to get curated job recommendations

TurnCare is Hiring for 5 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →